DDInter973 DDInter782
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Irinotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Irinotecan {u} (Compound) treats {v} (Disease) hematologic cancer
Irinotecan {u} (Compound) binds {v} (Gene) ABCC1
Irinotecan {u} (Compound) upregulates {v} (Gene) PHLDA3
Irinotecan {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Irinotecan {u} (Compound) downregulates {v} (Gene) PCMT1
Irinotecan {u} (Compound) causes {v} (Side Effect) Febrile neutropenia
Irinotecan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Irinotecan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Irinotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Verapamil
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Irinotecan (Compound) treats hematologic cancer (Disease)
Irinotecan (Compound) binds ABCC1 (Gene)
Irinotecan (Compound) upregulates PHLDA3 (Gene)
Irinotecan (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Irinotecan (Compound) downregulates PCMT1 (Gene)
Irinotecan (Compound) causes Febrile neutropenia (Side Effect)
Irinotecan may cause a minor interaction that can limit clinical effects when taken with Enoxacin
Irinotecan may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Verapamil